Skip to main content
. 2022 Feb 26;15:28. doi: 10.1186/s13048-022-00957-7

Fig. 3.

Fig. 3

Average PNP-binding to NK cells at time points of clinical evets during 8/2017 to 4/2019. Legend: A rise in NK cell PNP-binding started after beginning Bevacizumab in 10/2017 and resuming it in 12/2018. The patient had two abdominal surgeries indicated by the green and red arrows. The start and end points of the Onalespib/Olaparib cycles are indicated in the yellow background section with each cycle beginning with I.V. administrations of Onalespib